Roquefort Therapeutics (LON:ROQ) Stock Price Down 2.1% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ)’s share price dropped 2.1% on Thursday . The stock traded as low as GBX 3.50 ($0.04) and last traded at GBX 3.77 ($0.05). Approximately 1,022,574 shares were traded during mid-day trading, a decline of 21% from the average daily volume of 1,298,604 shares. The stock had previously closed at GBX 3.85 ($0.05).

Roquefort Therapeutics Stock Down 10.6 %

The stock’s fifty day simple moving average is GBX 4.24 and its 200-day simple moving average is GBX 4.11. The stock has a market cap of £4.68 million, a P/E ratio of -362.00 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.